Astera Labs, Inc. (NASDAQ:ALAB) reported a director sale on April 1, 2026, when Manuel Alba executed sales of 183,730 shares of the company's common stock. The transaction was carried out through a pre-arranged 10b5-1 trading plan and produced total proceeds of approximately $19.7 million, according to the Form 4 filing.
Details of the sale
The share disposals were completed in multiple tranches at weighted average prices spanning from $106.3194 to $111.1412 per share. The filing itemizes the volumes and average prices as follows:
| Shares Sold | Weighted Average Price |
|---|---|
| 57,001 | $106.3194 |
| 24,317 | $107.4443 |
| 45,668 | $108.3324 |
| 15,367 | $109.1027 |
| 5,060 | $110.2112 |
| 2,587 | $111.1412 |
| 33,000 | $107.6141 |
After these transactions, Alba directly and indirectly holds 1,733,312 shares of Astera Labs common stock.
Market context and valuation notes
The sales come against a backdrop of notable share-price swings. The stock has fallen 42% over the past six months while delivering a 110% gain over the trailing 12 months. An InvestingPro note cited in the filing highlights that Astera Labs' stock price movements are quite volatile. In addition, InvestingPro analysis indicates the shares are currently trading above their Fair Value, categorizing the company among overvalued stocks in the market.
Recent financial performance
Astera Labs reported strong fourth-quarter 2025 results. The company posted earnings per share of $0.58 for the quarter, exceeding the forecasted $0.51 by 13.73%. Revenue in Q4 reached $270.6 million, representing a 92% year-over-year increase. The results underscore a period of accelerating top-line growth and earnings strength. The stock experienced movement in after-hours trading following the release of those figures.
What remains uncertain
The filing and accompanying market commentary do not provide additional context for the purpose behind the 10b5-1 plan sale or any follow-on intentions for Alba's remaining share position. Observers will therefore need to rely on the publicly filed information and subsequent disclosures to assess any broader implications.
Overall, the transaction is a large, pre-planned insider sale that occurred while the company showed strong quarterly results but traded with substantial volatility and a valuation assessment that some sources view as above fair value.